The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization
- 51 Downloads
Trimetazidine has been shown to prevent the risk of contrast-induced nephropathy (CIN) in patients with renal dysfunction undergoing percutaneous coronary intervention (PCI). However, the effect of trimetazidine on CIN in unselected patients is unknown. We aimed to evaluate the effect of trimetazidine on preventing CIN in unselected patients treated with PCI.
2154 consecutive patients were enrolled and divided into the trimetazidine (n = 529) and non-trimetazidine group (n = 1625). Patients in the trimetazidine group received trimetazidine 20 mg thrice daily starting at least 24 h before the procedure and continuing until discharge. The primary outcome was CIN.
CIN was observed in 197 (9.2%) patients. The incidence of CIN was similar between two groups (9.1% vs. 9.2%, P = 0.947). After adjusting for other potential risk factors, trimetazidine did not significantly reduce the risk of CIN (OR = 0.70, 95% CI 0.46–1.08, P = 0.104). The results remained similar when using the alternate definitions of CIN and different subgroup analysis based on diabetes or chronic kidney disease. In additional, no significant difference between two groups was found with respect to in-hospital major adverse clinical events (1.89% vs. 1.66%, P > 0.05).
Trimetazidine did not exert significant renal protective effect on preventing CIN and in hosptial major adverse clinical events in unselected patients undergoing PCI.
KeywordsTrimetazidine Contrast-induced nephropathy Percutaneous coronary intervention Risk factors
This study was supported by a Grant from the National Science Foundation for Young Scientists of China (Grant No. 81800325) and Science and Technology Planning Project of Guangzhou City (201906010089), and Medical Science and Technology Research Funding of Guangdong (A2017347), and China Youth Research Funding (2017-CCA-VG-018), and the Medjaden Academy & Research Foundation for Young Scientists (Grant No. MJR20160025). The funders had no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript. The work was not funded by any industry sponsors. All authors agreed to submit the manuscript for publication.
Compliance with ethical standards
Conflict of interest
The authors of the present manuscript have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional.
Informed consent was obtained from all individual participants included in the study.
- 1.Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W (2012) A European renal best practice (ERBP) position statement on the kidney disease improving global outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 27(12):4263–4272CrossRefGoogle Scholar
- 2.Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, Veglia F, Fabbiocchi F, Montorsi P, Bartorelli AL (2012) Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC Cardiovasc Interv 5(1):90–97CrossRefGoogle Scholar
- 4.Abe M, Morimoto T, Akao M, Furukawa Y, Nakagawa Y, Shizuta S, Ehara N, Taniguchi R, Doi T, Nishiyama K, Ozasa N, Saito N, Hoshino K, Mitsuoka H, Toma M, Tamura T, Haruna Y, Kita T, Kimura T (2014) Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol 114(3):362–368CrossRefGoogle Scholar
- 18.Steg PG, Grollier G, Gallay P, Morice M, Karrillon GJ, Benamer H, Kempf C, Laperche T, Arnaud P, Sellier P (2001) A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 77(2):263–273CrossRefGoogle Scholar